IMUX
Immunic, Inc.
Set alert
- YTD
- +40.64%
- 1 year
- -4.21%
- Open
- 7.70
- Prev close
- 7.80
- Mkt cap
- 102.47M
- Vol
- 244.43K
- Avg vol
- 335.47K
- EPS
- -3.83
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.37
- High
- 7.78
- Forward P/E
- -1.67
- Beta
- 1.88
- Short ratio
- 4.69
- Inst. own
- 64.85%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.24
- 200-d avg
- 1.32
- 1y target
- 12.79
Key statistics
- Market cap
- 96.38M
- Enterprise value
- 31.91M
- Trailing P/E
- 0.00
- Forward P/E
- -1.67
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.34
- EPS (TTM)
- -1.23
- Beta
- 1.88
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -45.13M
- Total cash
- 59.07M
- Total debt
- 899.00K
- Return on equity
- -216.24%
- Shares outstanding
- 90.08M
- Short % of float
- 4.70%
- 50-day average
- 1.24
- 200-day average
- 1.32
Analyst view
Consensus: none
- Target (low)
- 5.00
- Target (mean)
- 12.79
- Target (high)
- 28.00
- Strong buy2
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.23857.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.22 | -0.24 | -0.02 | -9.09% |
| Aug 8, 2024 | Jun 1, 2024 | -0.23 | -0.21 | +0.02 | +8.70% |
| May 8, 2024 | Mar 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Feb 22, 2024 | Dec 1, 2023 | -0.51 | -0.48 | +0.03 | +5.88% |
| Nov 14, 2023 | Sep 1, 2023 | -0.55 | -0.51 | +0.04 | +7.27% |
| Aug 3, 2023 | Jun 1, 2023 | -0.52 | -0.54 | -0.02 | -3.85% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | HC Wainwright & Co. | init | — | Buy |
| Nov 7, 2024 | EF Hutton | main | Buy | Buy |
| Oct 22, 2024 | EF Hutton | main | Buy | Buy |
| Sep 18, 2024 | EF Hutton | main | Buy | Buy |
| Sep 16, 2024 | EF Hutton | init | — | Buy |
| Aug 27, 2024 | B. Riley Securities | init | — | Buy |
About Immunic, Inc.
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- imux.com
News
- Immunic to Host Virtual Progressive Multiple Sclerosis R&D Day on November 5, 2026
- Cantor Fitzgerald Initiates Coverage On Immunic with Overweight Rating
- Immunic Announces Acceptance Of Four Abstracts At MSToronto2026 – the 10th Joint ACTRIMS-ECTRIMS Meeting
- HC Wainwright & Co. Reiterates Buy on Immunic, Maintains $22 Price Target
- Wedbush Initiates Coverage On Immunic with Outperform Rating, Announces Price Target of $45
- Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate
- Immunic Announces Presentation Of One Late-Breaking And Two Additional Posters Highlighting Additional Data From Its Phase 2 CALLIPER Trial
- EXCLUSIVE: Immunic Appoints Former Genentech Exec Erik Lundgren As CEO
- B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27
- Immunic Appoints Michael W. Bonney As Board Chairman
Your note
Sign in to keep a note on IMUX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| RUDICK RICHARD ALAN | Director | Purchase | Nov 11, 2024 | 87,300 |
| VITT DANIEL | Chief Executive Officer | Purchase | Feb 25, 2024 | 0 |
| WHALEY GLENN | Chief Financial Officer | Purchase | May 14, 2023 | 25,510 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.88% | 8,902,972 | 9.53M | Sep 29, 2024 |
| Avidity Partners Management, LP | 9.18% | 8,266,000 | 8.84M | Sep 29, 2024 |
| Soleus Capital Management, L.P. | 8.10% | 7,293,007 | 7.80M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.21% | 5,594,406 | 5.99M | Sep 29, 2024 |
| Janus Henderson Group PLC | 5.66% | 5,099,278 | 5.46M | Sep 29, 2024 |
| Vanguard Group Inc | 5.22% | 4,700,016 | 5.03M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.92% | 2,629,603 | 2.81M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 2.08% | 1,870,577 | 2.00M | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.22% | 202,245 | 216.40K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 190,000 | 203.30K | Sep 29, 2024 |
| Vanguard Balanced Index Fund | 0.11% | 98,039 | 104.90K | Sep 29, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.08% | 69,930 | 74.83K | Sep 29, 2024 |